Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 5/20 | 0.45 |
| ▸ | LMNA | P02545 | 3/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 6/20 | 0.43 |
| ▸ | HTT | P42858 | 3/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.41 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL197873 | 0.76 | GSTO1 (0.36) | SMN1; SMN2KDM4EALDH1A1 | |
| SCHEMBL3265384 | 0.73 | LMNA (0.70) | TSHRLMNASMN1; SMN2HTTALDH1A1 | |
| SCHEMBL196165 | 0.69 | HTT (0.53) | TSHRLMNASMN1; SMN2HTTKDM4E | |
| SCHEMBL197382 | 0.69 | RAD51 (0.41) | TSHRLMNASMN1; SMN2HIF1A | |
| SCHEMBL9340848 | 0.67 | ALDH1A1 (0.52) | TSHRLMNASMN1; SMN2HTTKDM4E | |
| SCHEMBL197615 | 0.66 | ALDH1A1 (0.36) | SMN1; SMN2ALDH1A1KMT2ACYP2C19 | |
| SCHEMBL198435 | 0.66 | RAD51 (0.33) | — | |
| SCHEMBL822936 | 0.66 | TSHR (0.50) | TSHRLMNASMN1; SMN2HTTKDM4E | |
| SCHEMBL14010619 | 0.66 | ALDH1A1 (0.55) | TSHRLMNASMN1; SMN2HTTKDM4E | |
| SCHEMBL11938469 | 0.66 | TSHR (0.54) | TSHRLMNASMN1; SMN2HTTKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8293905-B2 | Bipyridine compound, transition metal complex, and method for production of conjugated aromatic compound using the transition metal complex | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2012-10-23 | — | — | US | disclosed |
| US-8088883-B2 | Transition metal complex and process for producing conjugated aromatic compound using the transition metal complex | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2012-01-03 | — | — | US | disclosed |
| US-20110046336-A1 | TRANSITION METAL COMPLEX AND PROCESS FOR PRODUCING CONJUGATED AROMATIC COMPOUND USING THE TRANSITION METAL COMPLEX | SUMITOMO CHEMICAL COMPANY, LIMITED | 2011-02-24 | — | — | US | disclosed |
| CN-101945839-A | Process for producing conjugated aromatic compound | SUMITOMO CHEMICAL CO | 2011-01-12 | — | — | CN | disclosed |
| US-20100292481-A1 | METHOD FOR PRODUCING CONJUGATED AROMATIC COMPOUND | SUMITOMO CHEMICAL COMPANY, LIMITED | 2010-11-18 | — | — | US | disclosed |
| EP-2233459-A1 | METHOD FOR PRODUCING CONJUGATED AROMATIC COMPOUND | Sumitomo Chemical Company, Limited (JP) | 2010-09-29 | — | — | EP | disclosed |
| CN-101827854-A | Transition metal complex and method for producing conjugated aromatic compound using same | SUMITOMO CHEMICAL CO | 2010-09-08 | — | — | CN | disclosed |
| US-20100184978-A1 | BIPYRIDINE COMPOUND, TRANSITION METAL COMPLEX, AND METHOD FOR PRODUCTION OF CONJUGATED AROMATIC COMPOUND USING THE TRANSITION METAL COMPLEX | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2010-07-22 | — | — | US | disclosed |
| CN-101772508-A | Bipyridine compound, transition metal complex, and method for production of conjugated aromatic compound using the transition metal complex | SUMITOMO CHEMICAL CO | 2010-07-07 | — | — | CN | disclosed |
| EP-2192124-A1 | TRANSITION METAL COMPLEX AND PROCESS FOR PRODUCING CONJUGATED AROMATIC COMPOUND WITH THE TRANSITION METAL COMPLEX | Sumitomo Chemical Company, Limited (JP) | 2010-06-02 | — | — | EP | disclosed |
| EP-2172470-A1 | BIPYRIDINE COMPOUND, TRANSITION METAL COMPLEX, AND METHOD FOR PRODUCTION OF CONJUGATED AROMATIC COMPOUND USING THE TRANSITION METAL COMPLEX | Sumitomo Chemical Company, Limited (JP) | 2010-04-07 | — | — | EP | disclosed |
| CN-101341183-A | Polyarylene and process for producing the same | SUMITOMO CHEMICAL CO (JP) | 2009-01-07 | — | — | CN | disclosed |
| US-20080287646-A1 | Polyarylene and Method for Producing the Same | SUMITOMO CHEMICAL COMPANY, LIMITED | 2008-11-20 | — | — | US | disclosed |
| EP-1935916-A1 | POLYARYLENE AND PROCESS FOR PRODUCING THE SAME | Sumitomo Chemical Company, Limited (JP) | 2008-06-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110046336-A1 | TRANSITION METAL COMPLEX AND PROCESS FOR PRODUCING CONJUGATED AROMATIC COMPOUND USING THE TRANSITION METAL COMPLEX | C9, C5, AP1M1 | TSHR 1144/4885LMNA 2664/4885SMN1; SMN2 3838/4885 |
| US-20100184978-A1 | BIPYRIDINE COMPOUND, TRANSITION METAL COMPLEX, AND METHOD FOR PRODUCTION OF CONJUGATED AROMATIC COMPOUND USING THE TRANSITION METAL COMPLEX | C9, C5, AP2M1 | TSHR 368/4885LMNA 3345/4885SMN1; SMN2 4123/4885 |
| US-20080287646-A1 | Polyarylene and Method for Producing the Same | CYP1A1, C1R, CBR1 | TSHR 307/4885LMNA 2889/4885SMN1; SMN2 4161/4885 |
| US-20100292481-A1 | METHOD FOR PRODUCING CONJUGATED AROMATIC COMPOUND | TYR, PAH, AHR | TSHR 2878/4885LMNA 2021/4885SMN1; SMN2 2455/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.